Related Experiment Video

Updated: Jan 20, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.5K

Correction to: The Advanced Development Pathway of the RTS,S/AS01 Vaccine

Lorenz von Seidlein1

  • 1Mahidol-Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. Lorenz@tropmedres.ac.

Methods in Molecular Biology (Clifton, N.J.)
|August 31, 2019
PubMed

Insights

Vaccine effectiveness in children is higher when administered between 6 and 12 weeks, with a booster at 20 months offering additional protection. This finding is crucial for pediatric immunization schedules.

Area of Science:

  • Pediatric Vaccinology
  • Immunology

Background:

  • Optimizing childhood vaccination schedules is critical for public health.
  • Accurate information on vaccine timing enhances protective efficacy.

Purpose of the Study:

  • To clarify the optimal age range for primary vaccination and booster doses in children.
  • To correct a previous publication regarding vaccine protective efficacy based on age at administration.

Main Methods:

  • This study involved a review of existing vaccination data.
  • Analysis focused on comparing vaccine effectiveness across different age groups for primary and booster doses.

Main Results:

  • Vaccination between 6 and 12 weeks of age demonstrated greater protective benefits compared to vaccination between 5 and 17 months.
  • A booster vaccination administered at 20 months of age provided supplementary protection.

Conclusions:

  • The findings underscore the importance of adhering to specific age windows for childhood immunizations.
  • Correcting the published data ensures accurate guidance for healthcare providers and improved child health outcomes.

More Related Videos

Surgical Correction for Pediatric Epiblepharon and Trichiasis03:59

Surgical Correction for Pediatric Epiblepharon and Trichiasis

Published on: July 8, 2025

532
Vaccines, APCs and Memory Cells01:51

Vaccines, APCs and Memory Cells

51.3K

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
51.3K
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Rescue of recombinant arenaviruses from cloned cDNAs, an approach referred to as reverse genetics, allows researchers to investigate the role of specific viral gene products, as well as the contribution of their different specific domains and residues, to many different aspects of the biology of arenavirus. Likewise, reverse genetics techniques in FDA-approved cell lines (Vero) for vaccine development provides novel possibilities for the generation of effective and safe vaccines to combat human...
17.5K
Surgical Correction for Pediatric Epiblepharon and Trichiasis03:59

Surgical Correction for Pediatric Epiblepharon and Trichiasis

Here, we present a protocol for surgical correction for pediatric epiblepharon and...
532
Distance Corrections01:15

Distance Corrections

To achieve precise distance measurements, especially in surveying and construction, certain corrections must be applied to account for potential sources of error like the standardization errors, temperature variations, and slope adjustments.Standardization error emerges when measurement equipment undergoes changes, such as wear, repairs, or weather impacts. To address this, surveyors compare the equipment’s readings to a standard. This process identifies any deviation that might lead to...
281
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

We present here an application for a standard immunological technique (CFSE stained OT-I proliferation) intended to rapidly monitor adjuvant-mediated cytotoxic T lymphocyte (CTL) generation in vivo. This fast estimation of CTL capacities is useful for the development of prophylactic vaccines against intracellular pathogens as well as therapeutic cancer...
9.2K
Power Factor Correction01:20

Power Factor Correction

The power transmission to a factory involves the transfer of apparent power, a combination of active and reactive power. The power factor measures how effectively electrical power is converted into useful work output. The ratio of the real power (KW) that does the work to the apparent power (KVA) supplied to the circuit.
498